| The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 KB Tran, JJ Lang, K Compton, R Xu, AR Acheson, HJ Henrikson, ... The Lancet 400 (10352), 563-591, 2022 | 395 | 2022 |
| Recent advances in the management of metastatic prostate cancer N Sayegh, U Swami, N Agarwal JCO Oncology Practice 18 (1), 45-55, 2022 | 90 | 2022 |
| Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer RP Graf, V Fisher, J Weberpals, O Gjoerup, MB Tierno, RSP Huang, ... JAMA network Open 5 (3), e225394-e225394, 2022 | 41 | 2022 |
| Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States U Swami, JA Sinnott, B Haaland, N Sayegh, TR McFarland, N Tripathi, ... Cancers 13 (19), 4951, 2021 | 30 | 2021 |
| SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer U Swami, RP Graf, RH Nussenzveig, V Fisher, H Tukachinsky, ... Clinical Cancer Research 28 (22), 4917-4925, 2022 | 24 | 2022 |
| Seeing the forest for the trees—single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer MY Koh, N Sayegh, N Agarwal Cancer Cell 39 (5), 594-596, 2021 | 23 | 2021 |
| Enhancing triage efficiency and accuracy in emergency rooms for patients with metastatic prostate cancer: a retrospective analysis of artificial intelligence-assisted triage … G Gebrael, KK Sahu, B Chigarira, N Tripathi, V Mathew Thomas, ... Cancers 15 (14), 3717, 2023 | 19 | 2023 |
| Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy J Graham, JC Wells, S Dudani, CL Gan, F Donskov, J Lee, ... European Journal of Cancer 171, 124-132, 2022 | 17 | 2022 |
| Radium-223 plus enzalutamide versus enzalutamide in metastatic castration-refractory prostate cancer: final safety and efficacy results BL Maughan, A Kessel, TR McFarland, N Sayegh, R Nussenzveig, ... The Oncologist 26 (12), 1006-e2129, 2021 | 16 | 2021 |
| Advances in the treatment of metastatic prostate cancer G Gebrael, GG Fortuna, N Sayegh, U Swami, N Agarwal Trends in Cancer, 2023 | 10 | 2023 |
| Women's sexual function before and during COVID‐19 pandemic: A systematic review and meta‐analysis K Hessami, N Sayegh, AS Abdolmaleki, S Bakht, S Qaderi, M Darabi, ... Journal of Obstetrics and Gynaecology Research 48 (9), 2285-2295, 2022 | 9 | 2022 |
| Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine … E Lin, AW Hahn, RH Nussenzveig, S Wesolowski, N Sayegh, ... The Oncologist 26 (9), 751-760, 2021 | 9 | 2021 |
| Body composition and metastatic prostate cancer survivorship AM Coletta, N Sayegh, N Agarwal Cancer treatment and research communications 27, 100322, 2021 | 9 | 2021 |
| Genomic and clinical prognostic factors in patients with advanced urothelial carcinoma receiving immune checkpoint inhibitors NS Chawla, N Sayegh, N Tripathi, A Govindarajan, ZB Zengin, EJ Phillip, ... Clinical Genitourinary Cancer 21 (1), 69-75, 2023 | 7 | 2023 |
| Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment AA Hamid, N Sayegh, B Tombal, M Hussain, CJ Sweeney, JN Graff, ... American Society of Clinical Oncology Educational Book 43, e390166, 2023 | 6 | 2023 |
| Cardiovascular toxicities associated with tyrosine kinase inhibitors N Sayegh, J Yirerong, N Agarwal, D Addison, M Fradley, J Cortes, ... Current cardiology reports 25 (4), 269-280, 2023 | 6 | 2023 |
| Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma N Dizman, A Govindarajan, ZB Zengin, L Meza, N Tripathi, N Sayegh, ... Clinical Genitourinary Cancer 21 (5), 530-536, 2023 | 5 | 2023 |
| The biology behind combining PARP and androgen receptor inhibition for metastatic castration resistant prostate cancer N Agarwal, T Zhang, E Efstathiou, N Sayegh, A Engelsberg, F Saad, ... European Journal of Cancer, 113249, 2023 | 5 | 2023 |
| Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results. A Kessel, TR McFarland, N Sayegh, K Morton, D Sirohi, M Kohli, U Swami, ... Journal of Clinical Oncology 39 (6_suppl), 135-135, 2021 | 5 | 2021 |
| Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis J Swaby, A Aggarwal, A Batra, A Jain, L Seth, N Stabellini, MS Bittencourt, ... Clinical genitourinary cancer 21 (3), e182-e189, 2023 | 4 | 2023 |
NEERAJ Agarwaluniversity of utahVerified email at hci.utah.edu
